A melanoma therapy produced responses in 10 of 15 patients. Five still had responses a year later.
Obsidian Therapeutics reported updated data for amsoki-cel, a melanoma therapy, showing a 67% objective response rate (10/15 patients) and 33% of patients (5/15) in ongoing response at 12 months. Median progression-free survival was 8.3 months. The therapy demonstrated a favorable safety profile. Topline data from the Phase 1/2 Agni-01 study is expected by year-end 2027. Obsidian is also investigating amsoki-cel in non-small cell lung cancer (NSCLC).
How this was made
The 30-second read
Why it matters
The data represent the first public efficacy readout for amsoki‑cel, a novel engineered TIL therapy, and could accelerate development timelines.
Market read
Positive trial data are likely to drive short‑term buying interest in OBX and may influence peer biotech stocks.
What to watch
Potential regulatory hurdles and manufacturing scalability may temper upside.
Background
Obsidian Therapeutics announced updated Phase 1/2 melanoma data, including 2 complete responses and 8 partial responses among 15 patients.
Ticker impact
Obsidian Therapeutics (OBX) released first‑time Phase 1/2 melanoma trial data showing 67% ORR and durable responses.
upward pressure as market prices in the encouraging efficacy data.
First disclosure of pivotal trial outcomes for a clinical‑stage biotech typically moves the stock sharply on the day of release.
Market effects
Strengthens the TIL cell‑therapy segment and may lift peer biotech valuations.
Positive for US biotech sector, modest impact on broader market.
Limited to biotech investors; no broad macro effect.
Counterpoint
If the data are not replicated in larger trials, the initial hype could fade quickly.
Key entities
- companyObsidian Therapeutics, Inc.
Clinical‑stage biotech developing engineered TIL therapies.
- productAmsoki‑cel
Engineered TIL cell therapy targeting advanced melanoma.
